Key Features of the Reports
- The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
- The report covers in-detail insights about the competitor’s overview, company share analysis, key market developments, and their key strategies
- The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
- The report tracks recent innovations, key developments, and start-up details that are actively working in the market
- The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
Immune Thrombocytopenia Market Segmentation
Frequently Asked Questions
2023 is the base year and 2030 is the forecast year.
The report covers the five regions and 15+ countries market data: North America (United States, Canada), Europe (Germany, France, Italy, Spain, and United Kingdom (UK), Asia Pacific (China, India, Japan, Australia & New Zealand), Latin America (Brazil, Mexico, Argentina) and Middle East and Africa (Saudi Arabia, United Arab Emirates, South Africa).
In our report, we provide 12-15 market players’ information into the report. However, based on the client’s request we will provide additional country and regional market players information as well.
1.Executive Summary
2.Global Immune Thrombocytopenia Market Introduction
2.1.Global Immune Thrombocytopenia Market - Taxonomy
2.2.Global Immune Thrombocytopenia Market - Definitions
2.2.1. By Drugs
2.2.2. By Type
2.2.3. By Distribution Channel
2.2.4. By Region
3.Global Immune Thrombocytopenia Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.7. Impact of COVID 19 on Market
4.Global Immune Thrombocytopenia Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Immune Thrombocytopenia Market By Drugs, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Avatrombopag
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Fostamatinib
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Eltrombopag
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Romiplostim
5.4.1.Romiplostim Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Caplacizumab-yhdp
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6.Global Immune Thrombocytopenia Market By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Acute Immune Thrombocytopenia
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Chronic Immune Thrombocytopenia
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7.Global Immune Thrombocytopenia Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Online Pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Retail Pharmacies
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8.Global Immune Thrombocytopenia Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9.North America Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drugs Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Avatrombopag
9.1.2.Fostamatinib
9.1.3.Eltrombopag
9.1.4.Romiplostim
9.1.5.Caplacizumab-yhdp
9.1.6.Others
9.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Acute Immune Thrombocytopenia
9.2.2.Chronic Immune Thrombocytopenia
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Online Pharmacies
9.3.2.Hospital Pharmacies
9.3.3.Retail Pharmacies
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Avatrombopag
10.1.2.Fostamatinib
10.1.3.Eltrombopag
10.1.4.Romiplostim
10.1.5.Caplacizumab-yhdp
10.1.6.Others
10.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Acute Immune Thrombocytopenia
10.2.2.Chronic Immune Thrombocytopenia
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.Online Pharmacies
10.3.2.Hospital Pharmacies
10.3.3.Retail Pharmacies
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Avatrombopag
11.1.2.Fostamatinib
11.1.3.Eltrombopag
11.1.4.Romiplostim
11.1.5.Caplacizumab-yhdp
11.1.6.Others
11.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Acute Immune Thrombocytopenia
11.2.2.Chronic Immune Thrombocytopenia
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Online Pharmacies
11.3.2.Hospital Pharmacies
11.3.3.Retail Pharmacies
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Latin America Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Avatrombopag
12.1.2.Fostamatinib
12.1.3.Eltrombopag
12.1.4.Romiplostim
12.1.5.Caplacizumab-yhdp
12.1.6.Others
12.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Acute Immune Thrombocytopenia
12.2.2.Chronic Immune Thrombocytopenia
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.Online Pharmacies
12.3.2.Hospital Pharmacies
12.3.3.Retail Pharmacies
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1.Brazil
12.4.2.Mexico
12.4.3.Rest of LA
13.Middle East and Africa Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1.Avatrombopag
13.1.2.Fostamatinib
13.1.3.Eltrombopag
13.1.4.Romiplostim
13.1.5.Caplacizumab-yhdp
13.1.6.Others
13.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1.Acute Immune Thrombocytopenia
13.2.2.Chronic Immune Thrombocytopenia
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1.Online Pharmacies
13.3.2.Hospital Pharmacies
13.3.3.Retail Pharmacies
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1.GCC Countries
13.4.2.South Africa
13.4.3.Rest of MEA
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.Argenx
14.2.2.Mylan
14.2.3.Sanofi
14.2.4.Pfizer Inc.
14.2.5.GlaxoSmithKline (GSK)
14.2.6.Eli Lilly and Company
14.2.7.Merck & Co.
14.2.8.Novartis
14.2.9.Rigel Pharmaceuticals, Inc.
14.2.10.hikma pharmaceuticals
15. Research Methodology
16. Appendix and Abbrevations
2.Global Immune Thrombocytopenia Market Introduction
2.1.Global Immune Thrombocytopenia Market - Taxonomy
2.2.Global Immune Thrombocytopenia Market - Definitions
2.2.1. By Drugs
2.2.2. By Type
2.2.3. By Distribution Channel
2.2.4. By Region
3.Global Immune Thrombocytopenia Market Dynamics
3.1. Drivers
3.2. Restraints
3.3. Opportunities/Unmet Needs of the Market
3.4. Trends
3.5. Product Landscape
3.7. Impact of COVID 19 on Market
4.Global Immune Thrombocytopenia Market Analysis, 2018-2022 and Forecast 2023-2029
4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%)
4.3. Market Opportunity Analysis
5.Global Immune Thrombocytopenia Market By Drugs, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
5.1. Avatrombopag
5.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.1.3. Market Opportunity Analysis
5.2. Fostamatinib
5.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.2.3. Market Opportunity Analysis
5.3. Eltrombopag
5.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.3.3. Market Opportunity Analysis
5.4. Romiplostim
5.4.1.Romiplostim Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.4.3. Market Opportunity Analysis
5.5. Caplacizumab-yhdp
5.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.5.3. Market Opportunity Analysis
5.6. Others
5.6.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
5.6.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
5.6.3. Market Opportunity Analysis
6.Global Immune Thrombocytopenia Market By Type, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
6.1. Acute Immune Thrombocytopenia
6.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.1.3. Market Opportunity Analysis
6.2. Chronic Immune Thrombocytopenia
6.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
6.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
6.2.3. Market Opportunity Analysis
7.Global Immune Thrombocytopenia Market By Distribution Channel, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
7.1. Online Pharmacies
7.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.1.3. Market Opportunity Analysis
7.2. Hospital Pharmacies
7.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.2.3. Market Opportunity Analysis
7.3. Retail Pharmacies
7.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
7.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
7.3.3. Market Opportunity Analysis
8.Global Immune Thrombocytopenia Market By Region, 2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
8.1. North America
8.1.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.1.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.1.3. Market Opportunity Analysis
8.2. Europe
8.2.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.2.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.2.3. Market Opportunity Analysis
8.3. Asia Pacific (APAC)
8.3.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.3.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.3.3. Market Opportunity Analysis
8.4. Latin America
8.4.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.4.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.4.3. Market Opportunity Analysis
8.5. Middle East and Africa
8.5.1. Market Analysis, 2018-2022 and Forecast, 2023-2029, (Sales Value USD Million)
8.5.2. Year-Over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
8.5.3. Market Opportunity Analysis
9.North America Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
9.1. Drugs Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.1.1.Avatrombopag
9.1.2.Fostamatinib
9.1.3.Eltrombopag
9.1.4.Romiplostim
9.1.5.Caplacizumab-yhdp
9.1.6.Others
9.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.2.1.Acute Immune Thrombocytopenia
9.2.2.Chronic Immune Thrombocytopenia
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.3.1.Online Pharmacies
9.3.2.Hospital Pharmacies
9.3.3.Retail Pharmacies
9.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
9.4.1.United States of America (USA)
9.4.2.Canada
10.Europe Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
10.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.1.1.Avatrombopag
10.1.2.Fostamatinib
10.1.3.Eltrombopag
10.1.4.Romiplostim
10.1.5.Caplacizumab-yhdp
10.1.6.Others
10.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.2.1.Acute Immune Thrombocytopenia
10.2.2.Chronic Immune Thrombocytopenia
9.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.3.1.Online Pharmacies
10.3.2.Hospital Pharmacies
10.3.3.Retail Pharmacies
10.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
10.4.1.Germany
10.4.2.France
10.4.3.Italy
10.4.4.United Kingdom (UK)
10.4.5.Spain
10.4.6.Rest of EU
11.Asia Pacific (APAC) Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
11.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.1.1.Avatrombopag
11.1.2.Fostamatinib
11.1.3.Eltrombopag
11.1.4.Romiplostim
11.1.5.Caplacizumab-yhdp
11.1.6.Others
11.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.2.1.Acute Immune Thrombocytopenia
11.2.2.Chronic Immune Thrombocytopenia
10.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.3.1.Online Pharmacies
11.3.2.Hospital Pharmacies
11.3.3.Retail Pharmacies
11.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
11.4.1.China
11.4.2.India
11.4.3.Australia and New Zealand (ANZ)
11.4.4.Japan
11.4.5.Rest of APAC
12.Latin America Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
12.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.1.1.Avatrombopag
12.1.2.Fostamatinib
12.1.3.Eltrombopag
12.1.4.Romiplostim
12.1.5.Caplacizumab-yhdp
12.1.6.Others
12.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.2.1.Acute Immune Thrombocytopenia
12.2.2.Chronic Immune Thrombocytopenia
11.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.3.1.Online Pharmacies
12.3.2.Hospital Pharmacies
12.3.3.Retail Pharmacies
12.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
12.4.1.Brazil
12.4.2.Mexico
12.4.3.Rest of LA
13.Middle East and Africa Immune Thrombocytopenia Market ,2018-2022 and Forecast 2023-2029 (Sales Value USD Million)
13.1. Drugs Analysis and Forecast by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.1.1.Avatrombopag
13.1.2.Fostamatinib
13.1.3.Eltrombopag
13.1.4.Romiplostim
13.1.5.Caplacizumab-yhdp
13.1.6.Others
13.2. Type Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.2.1.Acute Immune Thrombocytopenia
13.2.2.Chronic Immune Thrombocytopenia
12.3. Distribution Channel Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.3.1.Online Pharmacies
13.3.2.Hospital Pharmacies
13.3.3.Retail Pharmacies
13.4. Country Analysis 2018-2022 and Forecast 2023-2029 by Sales Value USD Million, Y-o-Y Growth (%), and Market Share (%)
13.4.1.GCC Countries
13.4.2.South Africa
13.4.3.Rest of MEA
14. Competition Landscape
14.1. Market Player Profiles (Introduction, Brand/Product Sales, Financial Analysis, Product Offerings, Key Developments, Collaborations, M & A, Strategies, and SWOT Analysis)
14.2.1.Argenx
14.2.2.Mylan
14.2.3.Sanofi
14.2.4.Pfizer Inc.
14.2.5.GlaxoSmithKline (GSK)
14.2.6.Eli Lilly and Company
14.2.7.Merck & Co.
14.2.8.Novartis
14.2.9.Rigel Pharmaceuticals, Inc.
14.2.10.hikma pharmaceuticals
15. Research Methodology
16. Appendix and Abbrevations
Argenx
Mylan
Sanofi
Pfizer Inc.
GlaxoSmithKline (GSK)
Eli Lilly and Company
Merck & Co.
Novartis
Rigel Pharmaceuticals, Inc.
Hikma pharmaceuticals
Mylan
Sanofi
Pfizer Inc.
GlaxoSmithKline (GSK)
Eli Lilly and Company
Merck & Co.
Novartis
Rigel Pharmaceuticals, Inc.
Hikma pharmaceuticals